Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425672 · ClinicalTrials.gov registry record · Phase 1
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
A Phase 1 study of Stage IV Breast Cancer and Stage IIIA Breast Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00425672 is a Phase 1 study of Stage IV Breast Cancer and Stage IIIA Breast Cancer that has completed, run by University of Washington. The registered enrollment target is 15 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00425672, a Phase 1 study of Stage IV Breast Cancer and Stage IIIA Breast Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: ONTAK may be able to help reduce the type of cells that prevent other types of immune cells from attacking the breast cancer cells. PURPOSE: This phase I/II trial is studying the safety of ONTAK and its possible side effects to see how well it works in treating patients with advanced breast cancer that did not respond to previous treatment.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER immunohistochemistry staining method
- OTHER flow cytometry
- OTHER enzyme-linked immunosorbent assay
- BIOLOGICAL ONTAK
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425672
The ClinicalTrials.gov registry entry for NCT00425672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (77% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00425672 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00425672 about?
NCT00425672 is a clinical study titled "ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment". RATIONALE: ONTAK may be able to help reduce the type of cells that prevent other types of immune cells from attacking the breast cancer cells. PURPOSE: This phase I/II trial is studying the safety of ONTAK and its possible side effects to see how well it works in treating patients with advanced bre...
What is the current status of trial NCT00425672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2005-09.
What conditions does trial NCT00425672 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Recurrent Breast Cancer.
What interventions are being tested in trial NCT00425672?
The interventions under investigation include: laboratory biomarker analysis (OTHER), immunohistochemistry staining method (OTHER), flow cytometry (OTHER), enzyme-linked immunosorbent assay (OTHER), ONTAK (BIOLOGICAL).
Who is sponsoring clinical trial NCT00425672?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425672 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
-
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
COMPLETED · Phase 1
-
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.